These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Tomizawa D; Miyamura T; Imamura T; Watanabe T; Moriya Saito A; Ogawa A; Takahashi Y; Hirayama M; Taki T; Deguchi T; Hori T; Sanada M; Ohmori S; Haba M; Iguchi A; Arakawa Y; Koga Y; Manabe A; Horibe K; Ishii E; Koh K Blood; 2020 Oct; 136(16):1813-1823. PubMed ID: 32845001 [TBL] [Abstract][Full Text] [Related]
13. Outcome of recurrent or refractory acute lymphoblastic leukemia in infants with MLL gene rearrangements: A report from the Japan Infant Leukemia Study Group. Tomizawa D; Koh K; Hirayama M; Miyamura T; Hatanaka M; Saikawa Y; Ishii E Pediatr Blood Cancer; 2009 Jul; 52(7):808-13. PubMed ID: 19229974 [TBL] [Abstract][Full Text] [Related]
14. Evolution and optimization of therapies for acute lymphoblastic leukemia in infants. Tomizawa D Int J Hematol; 2023 Feb; 117(2):162-172. PubMed ID: 36441356 [TBL] [Abstract][Full Text] [Related]
15. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Tomizawa D; Koh K; Sato T; Kinukawa N; Morimoto A; Isoyama K; Kosaka Y; Oda T; Oda M; Hayashi Y; Eguchi M; Horibe K; Nakahata T; Mizutani S; Ishii E Leukemia; 2007 Nov; 21(11):2258-63. PubMed ID: 17690691 [TBL] [Abstract][Full Text] [Related]